InsidersTradesSigma
Track the Inhibrx, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Health Care sector, Inhibrx, Inc. has logged 30 reports. Market capitalisation: €1.3bn. The latest transaction was reported on 3 June 2024 (J). Among the most active insiders: Eckelman Brendan P.. Every trade is accessible without an account.
30
Insider Decl.
n/a
Thresholds
€40m
2 ops.
Buy Volume
€191m
23 ops.
Sell Volume
37Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 June 2024
Declarations30 total
6,305,866 shares@ US$30.0081.4% of flowCommon StockSEC:0000905148-24-001667:0
300,000 shares@ US$34.3066.1% of flowCommon StockSEC:0000950142-24-001497:0
598,257 shares@ US$30.00100.0% of flowCommon StockSEC:0000950142-24-001498:0
3,224,301 shares@ US$30.0099.3% of flowCommon StockSEC:0000950142-24-001499:0
2,486,192 shares@ US$30.0097.8% of flowCommon StockSEC:0000950142-24-001500:0
511,627 shares@ US$19.354.3% of flowCommon StockSEC:0000905148-23-000804:0
Canonical exit: 26 Nov 2023 (T+90)
39,600 shares@ US$24.20076.3% of flowCommon StockSEC:0001739614-23-000016:0
60 shares@ US$25.02080.0% of flowCommon StockSEC:0001739614-23-000014:0
13,449 shares@ US$24.29252.1% of flowCommon StockSEC:0001739614-23-000012:0
21,665 shares@ US$25.35720.7% of flowCommon StockSEC:0001739614-23-000010:0
9,500 shares@ US$25.26310.2% of flowCommon StockSEC:0001739614-23-000008:0
22,213 shares@ US$23.4123.4% of flowCommon StockSEC:0001739614-23-000006:0
7,541 shares@ US$26.86530.2% of flowCommon StockSEC:0001739614-22-000132:0
25,246 shares@ US$25.53370.9% of flowCommon StockSEC:0001739614-22-000130:0
20,927 shares@ US$26.83483.7% of flowCommon StockSEC:0001739614-22-000128:0
2,733 shares@ US$29.32790.1% of flowCommon StockSEC:0001739614-22-000126:0
6,959 shares@ US$25.35960.2% of flowCommon StockSEC:0001739614-22-000124:0
27,651 shares@ US$33.3356.5% of flowCommon StockSEC:0001739614-22-000114:0
3,572 shares@ US$29.38890.1% of flowCommon StockSEC:0001739614-22-000109:0
8,981 shares@ US$28.66260.4% of flowCommon StockSEC:0001739614-22-000107:0
1,000,000 shares@ US$29.999914.3% of flowCommon StockSEC:0001140361-22-036956:0
Canonical exit: 5 Jan 2023 (T+90)
1,448 shares@ US$24.66880.2% of flowCommon StockSEC:0001739614-22-000105:0
160,000 shares0Common StockSEC:0001739614-22-000097:0
37,507 shares@ US$14.8573.9% of flowCommon StockSEC:0001739614-22-000095:0
11,900 shares0Common StockSEC:0001739614-22-000093:0
25 of 30 declarations
About Inhibrx, Inc.
Inhibrx, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and other serious diseases. The company is listed on NASDAQ under the ticker INBX.